Antimicrobial therapy for Pseudomonas aeruginosa: Therapeutic issues; Resistance; Pneumonia; Endocarditis; and infections of the GI tract, bone and joint, and urinary tract

Infections in Medicine

Volumn 15, Issue 6, 1998, Pages 385-394

  Kovacs, Kinga ^a   Paterson, David L ^b,c   Yu, Victor L ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Aminoglycosides; Endocarditis; Infec tion, gastrointestinal; Infection, urinary tract; Infections, bone and joint; Penicillin; Pneumonia; Pseudomonas aeruginosa; Quinolones

Indexed keywords

ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; GRAM NEGATIVE INFECTION; HUMAN; NEUTROPENIA; OPPORTUNISTIC INFECTION; PSEUDOMONAS AERUGINOSA; REVIEW; TREATMENT PLANNING;

EID: 0031807222     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Costerton JW, Anwar H: Pseudomonas aeruginosa: The microbe and pathogen, in Baltch AL, Smith RP (eds): Pseudomonas aeruginosa Infections and Treatment. New York, Marcel Dekker, 1994, pp 1-20.
2. Jackson GG, Riff LJ: Pseudomonas bacteremia: Pharmacologic and other bases for failure of treatment with gentamicin. J Infect Dis 124(suppl):S185-S198, 1971.
3. Bodey GP, Jadeja L, Elting L: Pseudomonas bacteremia: Retrospective analysis of 410 episodes. Arch Intern Med 145:1621-1629, 1985.
4. Anderson ET, Young LS, Hewitt W: Antimicrobial synergism in the therapy of gram-negative rod bacteremia. Chemotherapy 24:45-54, 1978.
5. Chan EL, Zabrinsky RJ: Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 6:157-164, 1987.
6. Hilf M, Yu VL, Sharp J, et al: Antibiotic therapy for Pseudomonas aeruginosa bacteremia: Outcome correlations in a prospective study of 100 patients. Am J Med 87:540-546, 1989.
7. Chandrasekar PH, Crane LR, Bailey EJ: Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infections by Pseudomonas aeruginosa in nonneutropenic patients. Antimicrob Agents Chemother 9:321-329, 1987.
8. Pizzo PA, Hathorn JW, Hiemenz J: A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315:552-558, 1986.
9. EORTC International Antimicrobial Therapy Group: Ceftazidime combined with short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 317:1692-1698, 1987.
10. Traub WH, Spohr M, Bauer D: Pseudomonas aeruginosa: In vitro susceptibility to antimicrobial drugs, single and combined, with and without defibrinated human blood. Chemotherapy 34:284-297, 1988.
11. Valdes JM, Baltch A, Smith RP, et al: The effect of rifampicin or the in vitro activity of cefopirime or ceftazidime in combination with aminoglycosides against Pseudomonas aeruginosa. J Antimicrob Chemother 25:575-584, 1990.
12. Zuravleff JJ, Yu VL, Yee RB: Ticarcillin-tobramycin-rifampin: In vitro synergy of the triplet combination against Pseudomonas aeruginosa. J Lab Clin Med 101:896-902, 1983.
13. Korvick JA, Peacock JE, Muder RR, et al: Addition of rifampin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: Prospective trial using the Zelen protocol. Antimicrob Agents Chemother 36:620-625, 1992.
14. Dejace P, Klatersky J: Comparative review of combination therapy: Two beta-lactams versus beta-lactam plus aminoglycoside. J Med 80(suppl 6B):29-38, 1986.
15. Johnson DE, Thompson B: Efficacy of single-agent therapy with azlocillin, ticarcillin, and amikacin, and beta-lactam/amikacin combinations for the treatment of Pseudomonas aeruginosa bacteremia in granulocytopenic rats. AmJ Med 89(suppl 5C):S53-S58, 1986.
16. Winston DJ, Barnes RC, Ho WG, et al: Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenia patients. Am J Med 77:442-450, 1984.
17. Craig WA, Ebert SC: Antimicrobial therapy in Pseudomonas aeruginosa infections, in Baltch AL, Smith RP (eds): Pseudomonas aeruginosa Infections and Treatment. New York, Marcel Dekker, 1994, pp 441-518.
18. Sanders CC: Chromosomal cephalosporinases responsible for multiple resistance to newer beta-lactam antibiotics. Ann Rev Microbiol 41:573-593, 1987.
19. Godrey AJ, Byran LE, Rabin HR: Beta-lactam-resistant Pseudomonas aeruginosa with modified penicillin-binding proteins emerging during cystic fibrosis treatment. Antimicrob Agents Chemother 19:705-711, 1981.
20. Angus BL, Carey AM, Caron DA, et al: Outer membrane permeability in Pseudomonas aeruginosa; comparison of wild-type with an antibiotic supersusceptible mutant. Antimicrob Agents Chemother 21:299-309, 1982.
21. Watanabe M, Iyobe S, Inoue M, et al: Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 35:147-151, 1991.
22. Minami S, Akama M, Araki H: Imipenem and cephem resistant Pseudomonas aeruginosa carrying plasmids coding for class B beta-lactamase. J Antimicrob Chemother 37:433-444, 1996.
23. Senda CC, Arakawa Y, Nakashima K: Multifocal outbreaks of metallo-beta-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum beta-lactams, including carbapenem. Antimicrob Agents Chemother 40:349-353, 1996.
24. Rasmussen BA, Bush K: Carbapenem-hydrolyzing beta-lactamases. Antimicrob Agents Chemother 41:223-232, 1997.
25. Quinn JP, DiVincenzo CA, Lerner SA: Resistance to imipenem in Pseudomonas aeruginosa: Clinical experience and biochemical mechanisms. Rev Infect Dis 10:892-898, 1988.
26. Trias J, Dufresne J, Levesque RC, et al: Decreased outer membrane permeability in imipenem-resistant mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother 33:1202-1206, 1989.
27. Sabath LD: Biochemical and physiologic basis for susceptibility and resistance of Pseudomonas aeruginosa to antimicrobial agents. Rev Infect Dis 6(suppl 3):S643-S656, 1984.
28. Hooper DC, Wolfson JS: Mechanisms of bacterial resistance to quinolones, in Hooper DC, Wolfson JS (eds): Quinolone Antimicrobial Agents, ed 2. Washington, DC, American Society for Microbiology, 1993.
29. Poole K: Bacterial multidrug resistance-emphasis on efflux mechanisms and Pseudomonas aeruginosa. J Antimicrob Chemother 34:453-456, 1994.
30. Centers for Disease Control: Guidelines for prevention of nosocomial pneumonia, MMWR Morb Mortal Wkly Rep 46(RR-1):1-79, 1997.
31. Henderson A, Kelly W, Wright M: Fulminant primary Pseudomonas aeruginosa pneumonia and septicaemia in previously well adults. Intensive Care Med 18:430-432, 1992.
32. Klatersky J, Huysmans D, Weerts C, et al: Endotracheally administered gentamicin for the prevention of infections of the respiratory tract in patients with tracheostomy: A double blind study. Chest 65:650-654, 1974.
33. Schuller JP, Coppens I, Klatersky J: Effectiveness of mezlocillin and endotracheally administered sisomicin with or without parenteral sisomicin in the treatment of gram-negative bronchopneumonia. J Antimicrob Chemother 9:63-68, 1982.
34. Sorensen VJ, Horst H, Obeid F, et al: Endotracheal aminoglycoside in gram negative pneumonia. Am Surg 52:391-394, 1986.
35. Brown RB, Kruse JA, Counts GW, et al: Double-blind study of endotracheal tobramycin in the treatment of gram-negative bactericidal pneumonia. Antimicrob Agents Chemother 34:269-272, 1990.
36. Haddow A, Greene S, Heinz G, et al: Ciprofloxacin (intravenous/oral) versus ceftazi-dime in lower respiratory tract infections. Am J Med 87(suppl 5A):S113-S115, 1989.
37. Kahn FA, Basin R: Sequential intravenous-oral administration of ciprofloxacin vs. ceftazidime in serious bacterial respiratory tract infection. Chest 96:528-537, 1989.
38. Kemmerich B, Small G, Pennington JE: Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa. Antimicrob Agents Chemother 29:395-399, 1986.
39. Fink MP, Snydman DR, Niederman MS, et al: Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenemcilastatin. Antimicrob Agents Chemother 38:547-557, 1994.
40. Jackson GG: Infective endocarditis caused by Pseudomonas aeruginosa, in Baltch AL, Smith RP (eds): Pseudomonas aeruginosa Infection and Treatment. New York, Marcel Dekker, 1994, pp 129-158.
41. Tablan OC, Reyes MP, Rintelmann WF, et al: Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in P aeruginosa endocarditis. J Infect Dis 149:257-263, 1984.
42. Daikos GL, Kathpalia S, Lolans V, et al: Long-term oral ciprofloxacin: Experience in the treatment of incurable infective endocarditis. Am J Med 84:786-790, 1988.
43. Uzun O, Erdal Akalin H, Unal S, et al: Long-term oral ciprofloxacin in the treatment of prosthetic valve endocarditis due to Pseudomonas aeruginosa. Scand J Infect Dis 24:707-800, 1992.
44. Agger WA, Mardan A: Pseudomonas aeruginosa infections of intact skin. Clin Infect Dis 20:302-308, 1995.
45. Rolston KVI, Bodey GP: Pseudomonas aeruginosa infection in cancer patients. Cancer Invest 10:43-59, 1992.
46. Pollock M: Pseudomonas, in Gorbach SL, Bartlett JG, Blacklow N (eds): Infectious Diseases. Philadelphia, W.B. Saunders, 1992, pp 1502-1513.
47. Dan M, Sigeman-Igra Y, Pitlik S, et al: Oral ciprofloxacin treatment of Pseudomonas aeruginosa osteomyelitis. Antimicrob Agents Chemother 34:849-852, 1990.
48. Dellamonica P, Bernard E, Etesse H, et al: Evaluation of pefloxacin, ofloxacin, and ciprofloxacin in the treatment of 39 cases of chronic osteomyelitis. Eur J Clin Microbiol Infect Dis 8:1024-1030, 1989.
49. Gentry LO, Rodriguez GG: Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrob Agents Chemother 34:40-42, 1990.
50. Aquado JH, Arjona R, Valle R, et al: Prolonged oral ciprofloxacin treatment of recalcitrant and severe osteomyelitis. Proceedings of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Atlanta, Oct. 21-24, 1990. Abstract 980.
51. Ball P: Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: Clinical significance and therapeutic approaches. J Antimicrob Chemother 16(suppl F):S165-S169, 1990.
52. Jacobs RF, McCarthy R, Elser J: Pseudomonas osteochondritis complicating puncture wounds of the foot in children - A 10-year evaluation. J Infect Dis 4:657-661, 1989.
53. Kovacs K, Yu VL: Ahtipseudomonal antimicrobial agent therapy. Drugs of Today 30:155-170, 1994.
54. Visalli MA, Jacobs MR, Appelbaum PC: Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology. Antimicrob Agents Chemother 42:953-955, 1998.
55. Citron DM, Appleman MD: Comparative in vitro activities of trovafloxacin against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections. Antimicrob Agents Chemother 41:2312-2316, 1997.
56. Kuck NA, Jacobus NV, Petersen N, et al: Comparative in vitro and in vivo activities of piperacillin combined with the betalactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob Agents Chemother 33:1964-1969, 1989.